Home › Acute Biphenotypic Leukemia › South Dakota › Sioux Falls
Acute Biphenotypic Leukemia clinical trials in Sioux Falls, SD
3 studies for Acute Biphenotypic Leukemia are looking for participants at sites in and around Sioux Falls (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
RecruitingPhase 2
- Sanford USD Medical Center - Sioux Falls, Sioux Falls
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
RecruitingPhase 3
- Sanford USD Medical Center - Sioux Falls, Sioux Falls
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
RecruitingPhase 1/2
- Sanford USD Medical Center - Sioux Falls, Sioux Falls
Acute Biphenotypic Leukemia trials in other cities
- Seattle, WA15 studies
- Houston, TX11 studies
- New York City, NY10 studies
- Atlanta, GA9 studies
- Durham, NC8 studies
- Memphis, TN7 studies
- Chicago, IL7 studies
- Charlotte, NC6 studies
- Baldwin Park, CA6 studies
- Aurora, CO6 studies
- Philadelphia, PA6 studies
- Dallas, TX6 studies
Other studies in Sioux Falls
- Non-Small Cell Lung Cancer19 studies
- Breast Cancer18 studies
- Ovarian Cancer16 studies
- Lung Cancer14 studies
- Cancer (all types)13 studies
- Endometrial Cancer11 studies
- Metastatic Cancer10 studies
- Colorectal Cancer9 studies
- Head and Neck Squamous Cell Carcinoma9 studies
- Heart Failure7 studies
- Colon Cancer7 studies
- Triple-Negative Breast Cancer7 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.